Stifel Nicolaus Sticks to Its Buy Rating for SomaLogic (SLGC)

In a report released on November 14, Daniel Arias from Stifel Nicolaus reiterated a Buy rating on SomaLogic (SLGCResearch Report), with a price target of $8.00. The company’s shares closed yesterday at $2.69.

Arias covers the Healthcare sector, focusing on stocks such as PerkinElmer, Thermo Fisher, and Danaher. According to TipRanks, Arias has an average return of 0.0% and a 51.82% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SomaLogic with a $8.00 average price target, a 197.40% upside from current levels. In a report released on November 15, Cowen & Co. also maintained a Buy rating on the stock with a $8.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $14.09 and a one-year low of $2.63. Currently, SomaLogic has an average volume of 1.33M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CM Life Sciences II Inc is a blank check company.

Read More on SLGC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More